SLRN250117P12500
- 0.00
- 0.000.00%
Acelyrin Newsroom
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $5 to $20
Cautious Hold Rating for ACELYRIN, INC. Amid Uncertainties in Lonigutamab's Efficacy and Dosing
ACELYRIN Is Maintained at Neutral by Citigroup
Citigroup Maintains Neutral on Acelyrin, Lowers Price Target to $3
Nasdaq Down 1.5%; RPM Posts Upbeat Results
Dow Surges Over 100 Points; US Trade Deficit Widens In November
Wedbush Stays Positive on Viridian Shares After Acelyrin Data
Acelyrin Falls After Updating Mid-stage Trial Data for Eye Disease Drug
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
ACELYRIN, INC. (SLRN) Receives a Buy From TD Cowen
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Market-Moving News for January 7th
Wells Fargo Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $13
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $6
ACELYRIN Is Maintained at Neutral by HC Wainwright & Co.
ACELYRIN, INC.'s Lonigutamab Program: Balancing Innovation and Uncertainty With a Hold Rating
Acelyrin Analyst Ratings
Promising Phase 1/2 Results for ACELYRIN's Lonigutamab Support Buy Rating